{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinum-based+Chemotherapy&page=39", "query": { "intervention": "Platinum-based Chemotherapy", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 1751, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinum-based+Chemotherapy&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinum-based+Chemotherapy&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T06:50:17.090Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01918306", "title": "GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Estrogen Receptor Negative Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Triple Negative Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI", "type": "PROCEDURE" }, { "name": "GDC -0941", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 16, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01918306" }, { "nct_id": "NCT06538038", "title": "Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer", "Epidermal Growth Factor Receptor Gene Mutation", "Stage III Lung Cancer", "Stage IV Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Osimertinib + Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2024-09-17", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 146, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Emeryville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06538038" }, { "nct_id": "NCT01655225", "title": "A Study of LY3023414 in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Non-Hodgkin's Lymphoma", "Metastatic Breast Cancer", "Malignant Mesothelioma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "LY3023414", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2012-07-31", "completion_date": "2022-02-02", "has_results": false, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 6, "location_summary": "Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01655225" }, { "nct_id": "NCT01588431", "title": "Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck" ], "interventions": [ { "name": "Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2011-12", "completion_date": "2022-10-04", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01588431" }, { "nct_id": "NCT03228537", "title": "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Extrapleural Pneumonectomy", "type": "PROCEDURE" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Pleurectomy", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2018-07-16", "completion_date": "2027-09-18", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 174, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228537" }, { "nct_id": "NCT01261728", "title": "Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Gemcitabine and Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2010-12-14", "completion_date": "2025-08-06", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01261728" }, { "nct_id": "NCT01258634", "title": "A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteosarcoma", "Lung Metastases" ], "interventions": [ { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "PEG-filgrastim", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "2 Years to 35 Years" }, "enrollment_count": 2, "start_date": "2010-07", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-12-10", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01258634" }, { "nct_id": "NCT04107077", "title": "Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2025-09-09", "completion_date": "2026-12-20", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04107077" }, { "nct_id": "NCT00851877", "title": "Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 37, "start_date": "2009-03-01", "completion_date": "2015-08-03", "has_results": true, "last_update_posted_date": "2020-08-21", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00851877" }, { "nct_id": "NCT00057928", "title": "S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 0, "start_date": "2003-04", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2012-06-13", "last_synced_at": "2026-10-16T06:50:17.090Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057928" } ] }